These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 30837199

  • 1. Clinical presentation of delayed hemolytic transfusion reactions and hyperhemolysis in sickle cell disease.
    Fasano RM, Miller MJ, Chonat S, Stowell SR.
    Transfus Clin Biol; 2019 May; 26(2):94-98. PubMed ID: 30837199
    [Abstract] [Full Text] [Related]

  • 2. Alloimmunization in patients with sickle cell disease and underrecognition of accompanying delayed hemolytic transfusion reactions.
    Coleman S, Westhoff CM, Friedman DF, Chou ST.
    Transfusion; 2019 Jul; 59(7):2282-2291. PubMed ID: 31021439
    [Abstract] [Full Text] [Related]

  • 3. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.
    Talano JA, Hillery CA, Gottschall JL, Baylerian DM, Scott JP.
    Pediatrics; 2003 Jun; 111(6 Pt 1):e661-5. PubMed ID: 12777582
    [Abstract] [Full Text] [Related]

  • 4. Immuno-hematological findings in Delayed Hemolytic Transfusion Reaction (DHTR).
    Thonier V.
    Transfus Clin Biol; 2019 May; 26(2):102-108. PubMed ID: 30885514
    [Abstract] [Full Text] [Related]

  • 5. Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease.
    Balbuena-Merle R, Hendrickson JE.
    Transfus Clin Biol; 2019 May; 26(2):112-115. PubMed ID: 30857806
    [Abstract] [Full Text] [Related]

  • 6. Challenges in preventing and treating hemolytic complications associated with red blood cell transfusion.
    Chonat S, Arthur CM, Zerra PE, Maier CL, Jajosky RP, Yee MEM, Miller MJ, Josephson CD, Roback JD, Fasano R, Stowell SR.
    Transfus Clin Biol; 2019 May; 26(2):130-134. PubMed ID: 30979566
    [Abstract] [Full Text] [Related]

  • 7. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions.
    Aygun B, Padmanabhan S, Paley C, Chandrasekaran V.
    Transfusion; 2002 Jan; 42(1):37-43. PubMed ID: 11896310
    [Abstract] [Full Text] [Related]

  • 8. Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients.
    Dean CL, Maier CL, Chonat S, Chang A, Carden MA, El Rassi F, McLemore ML, Stowell SR, Fasano RM.
    Transfusion; 2019 May; 59(5):1698-1705. PubMed ID: 30848512
    [Abstract] [Full Text] [Related]

  • 9. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions.
    Pirenne F, Yazdanbakhsh K.
    Blood; 2018 Jun 21; 131(25):2773-2781. PubMed ID: 29724898
    [Abstract] [Full Text] [Related]

  • 10. Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature.
    Unnikrishnan A, Pelletier JPR, Bari S, Zumberg M, Shahmohamadi A, Spiess BD, Michael MJ, Harris N, Harrell D, Mandernach MW.
    Transfusion; 2019 Jun 21; 59(6):1907-1910. PubMed ID: 30768787
    [Abstract] [Full Text] [Related]

  • 11. Catastrophic Delayed Hemolytic Transfusion Reaction in a Patient With Sickle Cell Disease Without Alloantibodies: Case Report and Review of Literature.
    Jasinski S, Glasser CL.
    J Pediatr Hematol Oncol; 2019 Nov 21; 41(8):624-626. PubMed ID: 30179992
    [Abstract] [Full Text] [Related]

  • 12. Management of hemolytic transfusion reactions.
    Hendrickson JE, Fasano RM.
    Hematology Am Soc Hematol Educ Program; 2021 Dec 10; 2021(1):704-709. PubMed ID: 34889404
    [Abstract] [Full Text] [Related]

  • 13. Preventing antibody positive delayed hemolytic transfusion reactions in sickle cell disease: Lessons learned from a case.
    Rankin A, Webb J, Nickel RS.
    Transfus Med; 2022 Oct 10; 32(5):433-436. PubMed ID: 35318744
    [Abstract] [Full Text] [Related]

  • 14. Management of delayed hemolytic transfusion reaction in sickle cell disease: Prevention, diagnosis, treatment.
    Pirenne F, Bartolucci P, Habibi A.
    Transfus Clin Biol; 2017 Sep 10; 24(3):227-231. PubMed ID: 28669521
    [Abstract] [Full Text] [Related]

  • 15. Multiple hemolytic transfusion reactions misinterpreted as severe vaso-occlusive crisis in a patient with sickle cell disease.
    Dean CL, Maier CL, Roback JD, Stowell SR.
    Transfusion; 2019 Feb 10; 59(2):448-453. PubMed ID: 30412270
    [Abstract] [Full Text] [Related]

  • 16. Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series.
    Nickel RS, Hendrickson JE, Fasano RM, Meyer EK, Winkler AM, Yee MM, Lane PA, Jones YA, Pashankar FD, New T, Josephson CD, Stowell SR.
    Transfusion; 2016 Jan 10; 56(1):107-14. PubMed ID: 26509333
    [Abstract] [Full Text] [Related]

  • 17. The role of Complement in Post-Transfusion Hemolysis and Hyperhemolysis Reaction.
    Roumenina LT, Bartolucci P, Pirenne F.
    Transfus Med Rev; 2019 Oct 10; 33(4):225-230. PubMed ID: 31672341
    [Abstract] [Full Text] [Related]

  • 18. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction.
    Cullis JO, Win N, Dudley JM, Kaye T.
    Vox Sang; 1995 Oct 10; 69(4):355-7. PubMed ID: 8751307
    [Abstract] [Full Text] [Related]

  • 19. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab.
    Gupta S, Fenves A, Nance ST, Sykes DB, Dzik WS.
    Transfusion; 2015 Mar 10; 55(3):623-8. PubMed ID: 25257194
    [Abstract] [Full Text] [Related]

  • 20. Rates of delayed hemolytic transfusion reactions observed in a trauma center.
    Hasan RA, Asif M, Tuott EE, Stansbury LG, Hess JR.
    Transfusion; 2021 Jul 10; 61(7):2035-2040. PubMed ID: 33983627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.